Profile of atacicept and its potential in the treatment of systemic lupus erythematosus

Estafania Cogollo1,*, Marta Amaral Silva2,*, David Isenberg3
1Department of Internal Medicine, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; 2Department of Internal Medicine, Hospital Distrital da Figueira da Foz, Coimbra, Portugal; 3Centre for Rheumatology, Department of Medicine, University College London, London, UK
*These authors are regarded as equal first authors

Abstract: The importance of B cell activating factors in the generation of autoantibodies in patients with systemic lupus erythematosus (SLE) is now recognized. The two key factors, known as BAFF and APRIL, produced by a variety of cells including monocytes, dendritic cells and T cells, also help to regulate B cell maturation, function and survival. Biologic agents that block these factors have now been developed and tried out in large scale clinical trials in SLE patients. Benlysta which blocks BAFF has met some of its end points in clinical trials and is approved for use in patients with skin and joint disease who have failed conventional drugs. In contrast, clinical trials using atacicept which blocks both BAFF and APRIL have been more challenging to interpret. An early study in lupus nephritis was, mistakenly, abandoned due to serious infections thought to be linked to the biologic when in fact the dramatic fall in the immunoglobulin levels took place when the patients were given mycophenolate, prior to the introduction of the atacicept. Likewise the higher dose arm (150 mgm) of a flare prevention study was terminated prematurely when 2 deaths occurred. However, the mortality rate in this study was identical to that seen in the Benlysta studies and a post hoc analysis found a highly significant benefit for the 150mgm arm compared to the lower dose (75 mgm) and placebo arms. Other trials with both Benlysta and atacicept are on-going.

Keywords: cytokines, lupus nephritis, BLyS, APRIL

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease in which autoantibodies target a variety of self-antigens, leading to many clinical manifestations.1 Despite great improvement in outcome during the past 50 years, many patients continue to experience significant morbidity or even die prematurely.2,3 Lupus nephritis (LN) in particular is often a severe complication of SLE whose treatment may have significant toxicity and many patients do not achieve complete remission.4 It has been anticipated that biological drugs targeting key molecules or cells will optimize the treatment of SLE.3,5,6 Given the role of B lymphocytes in the pathogenesis of SLE, rituximab, a monoclonal antibody directed to CD20, was studied in this disease. After some disappointing results, interest focused on targeting B-cell activating factors like the B-lymphocyte stimulator (BLyS). Belimumab (monoclonal antibody to BLyS) was approved for the treatment of SLE. Atacicept is a fusion protein that blocks not only BLyS but also the proliferation-inducing ligand (APRIL), another B-cell activating factor. It seems reasonable to assume that neutralizing both BLyS and APRIL would have different biological consequences and be more efficacious than neutralization of BLyS alone.1,3,7,8 This article reviews the main published data about atacicept.
Background
Targeting B cells: the role of rituximab

B cells have been shown to be important in the pathogenesis of SLE and other autoimmune diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), and neuromyelitis optica. They play a key role mediating immune responses through autoantibody production and autoantigen presentation, interactions with T and dendritic cells and cytokine production. Autoantibodies directed against a large number of self-antigens in the nucleus, cytoplasm, and cell membranes develop and bind to their targets, leading to the formation of immune complexes. These complexes activate complement resulting in a cascade of inflammatory reactions. It was hoped that successfully targeting B cells would improve clinical outcome with fewer side effects than conventional therapies. Several strategies have been employed to target B-lymphocytes.

Interest initially focused on removing CD20 positive B-lymphocytes in patients with SLE using rituximab, a chimeric monoclonal antibody directed to CD20. Success was initially reported in case series of patients with active/refractory SLE. However, two double-blind controlled trials – EXPLORER and LUNAR, which evaluated rituximab in patients with non-renal lupus and with LN, respectively, showed disappointing results. These may reflect problems with trial design, notably the intensive use of concomitant glucocorticoids and immunosuppressives.

BLYS and APRIL: from belimumab to atacicept

The tumor necrosis factor (TNF) ligand superfamily has two related members that regulate B-cell maturation, function and survival: BLYS, also known as B-cell activating factor belonging to the TNF family (BAFF), and APRIL. These molecules are produced by monocytes, dendritic cells, macrophages, and T cells. BLYS is a type II transmembrane protein with 285 amino acids. When surface BLYS is cleaved by a furin protease, a soluble, biologically active 17 KDa molecule is released and binds to three receptors on the surface of B cells: B-cell maturation antigen (BCMA), transmembrane activator and calcium-modulating ligand interactor (TACI) and BR3 (also known as BAFFR). APRIL is synthetized as a type II transmembrane protein that is intracellularly proteolytically cleaved before the secretion of the biologically active form. APRIL binds to two BLYS receptors (BCMA and TACI) and also to the heparin sulfate proteoglycans. Both BLYS and APRIL enhance the survival of human memory B cells and thus promote their differentiation into plasma cells. This is likely to be mediated by their interaction with BCMA. Furthermore, it was suggested that the APRIL/BCMA/TACI interactions play an important role in immunoglobulin (Ig)A class switch recombination.

Studies have shown that the regulation of the pre-immune B cell pool depends upon BLYS/BR3 signaling and that mature primary B cells require BLYS for survival. Elevated BLYS levels allow B cells to pass the transitional checkpoint and become established in the mature follicular and marginal zone B cell pools. In contrast, reducing available BLYS may lead to a more rigorous selection and reduce mature B cell lifespan thus reducing the number of mature B cells. Analysis of BLYS deficient mice with lower numbers of mature B cells and of BLYS transgenic (Tg) mice developing severe B-cell hyperplasia support the notion of an important role for BLYS in B-cell maintenance. Repeated administration of BLYS to mice results in B cell expansion and polyclonal hypergammaglobulinemia. Unlike soluble BLYS, the role of membrane BLYS remains uncertain.

APRIL upregulates co-stimulatory molecules on B cells enhancing their antigen presentation function. One in vitro study reported that APRIL co-stimulates mouse T-cell proliferation. In addition, APRIL Tg mice have an increased T-cell survival. An increase in spleen weight and in the proportion of B cells in the spleen was observed after the administration of recombinant soluble APRIL to mice. Other authors reported an increase in the percentage of B cells in the peripheral lymph nodes in mice that overexpress a human APRIL transgene. An increase in IgM (in response to T-dependent and T-independent antigens) and in IgG (in response to T-independent antigens) was reported in APRIL Tg mice.

Interestingly, BLYS and APRIL also promote the survival of regulatory B cells which down-modulate immune responses. It remains unknown why the final effect of these cytokines in a given host is variably pro- or anti-autoimmune.

Signals from BLYS and APRIL induce proliferation of plasma cells and thus increased Ig production. Some of the antibodies produced are likely to be directed to self-antigens. Studies have demonstrated that constitutive overexpression of BLYS often leads to the development of SLE-like features (including high levels of circulating autoantibodies and renal Ig deposits) in BLYS-Tg non-autoimmune prone mice and accelerates target-organ (kidney) pathology in autoimmune prone mice. Although mice with a lifelong absence of BLYS were not protected from serological autoimmunity and renal pathology, they were
largely spared from clinically overt disease (severe proteinuria and premature death). Conversely, the role of APRIL in these pathologies is controversial. Two studies generated APRIL deficient mice and found conflicting results. In one of them, no effects on T and B cells’ development and in vitro function or in vivo humoral responses were observed. In the other group, although APRIL knockout mice had a normal T and B cell development and proliferation in vitro, they had an increased number of effector memory T cells, enlarged germinal centers and an increased IgG response to T-dependent antigens. These disparate results can be explained by the different mouse genetic background. In a study in which mice were genetically rendered APRIL deficient, the authors concluded that APRIL is not essential for the development of full blown SLE in mice and may play a protective role. In another trial, APRIL Tg mice did not display signs of autoimmunity. These results highlight the need for a study with an agent that selectively blocks APRIL without also blocking BLyS.

Increased levels of APRIL, BLyS homotrimers, and/or BLyS/APRIL heterotrimers have been observed in humans with various autoimmune disorders, including SLE, as well as in the arthritic joints of patients with inflammatory arthritis. In addition, high serum levels of BLyS and APRIL have been described in patients with MS and chronic lymphocytic leukemia (CLL). It is known that CLL patients with a low percentage of leukemic cells expressing BLyS or APRIL have a significantly longer overall survival than patients with BLyS- or APRIL-positive leukemic cells. In patients with SLE, the concentration of these cytokines positively correlates with disease severity and serological markers such as anti-double-stranded DNA antibody levels, suggesting that BLyS and APRIL play a significant role in the pathogenesis of this disease. Conflicting results were reported in another study where serum APRIL levels were reported to be inversely correlated with serum anti-dsDNA titers and clinical disease activity, suggesting that APRIL might play a protective role in SLE patients. Additional studies are needed to clarify the role of APRIL in this disease.

Reviewing the unsatisfactory results of some rituximab trials and the biological effects of BLyS, it is reasonable to ask whether the indirect targeting of B cells via a survival factor might be preferable to targeting the B cells directly. Studies in mice strongly suggest that some autoreactive B cells have a greater dependency on BLyS for their survival than do non-autoreactive B cells and, thus, blocking BLyS could preferentially eliminate pathogenic B cells while sparing protective B cells. Furthermore, mice that over-express BLyS inflammatory responses are deviated toward a T helper 1 cell profile and away from a Th2 cell profile via a B-cell–independent pathway. Moreover, through direct effects on T cells, BLyS promotes in vitro generation of Th17 cells. Thus, targeting BLyS may not only target pathogenic B cells but also potentially, pathogenic Th1 and/or Th17 cells.

Belimumab was developed as an alternative approach to B-cell-directed therapy. It is a human IgG1κ monoclonal antibody that binds soluble human BLyS and inhibits its biologic activities. Belimumab was designed to avoid direct killing of B cells, by preventing antibody-dependent cell cytotoxicity, and the complement activation cascade. A Phase II trial was performed to evaluate efficacy and safety of belimumab in patients with active SLE with a SELENA-SLEDAI (Safety of Estrogen in Lupus Erythematosus National Assessment – Systemic Lupus erythematosus Disease activity Index) score of ≥4. Patients were randomized to belimumab plus standard-of-care or placebo and followed up for 52 weeks. Co-primary efficacy endpoints were the percentage change in SELENA-SLEDAI from baseline to week 24 and time to first flare. Although belimumab was biologically active, as demonstrated by reductions in some B cell populations, Ig levels and anti-dsDNA antibodies, there was no significant reduction of SLE disease activity or flares in patients treated with this drug compared to placebo. In a post hoc analysis of the Phase II trial, belimumab had significant, albeit modest benefit in patients with SLE. BLISS (Belimumab in subjects with Systemic Lupus Erythematosus) 52 and BLISS 76 were Phase III double-blind, randomized, controlled trials performed in patients with serologically active SLE with SELENA-SLEDAI scores of ≥6. Patients had primarily cutaneous and musculoskeletal manifestations of SLE. The primary endpoint was the SLE responder index (SRI) response rate at week 52 (an SRI response was defined as ≥4 point reduction in SELENA-SLEDAI score, no new British Isles Lupus Assessment Group A organ domain score and no more than one new British Isles Lupus Assessment Group B score, and no worsening in physician’s global assessment score versus baseline). In both studies, patients treated with belimumab plus standard-of-care had significantly improved SRI response rates compared with placebo. Pooled analyses of these trials confirmed a modest, but statistically significant, therapeutic effect of belimumab in SLE. Nevertheless, the results were disappointing because overall the degree of improvements in those patients given belimumab was not impressively different from those given...
placebo. These results might be explained by the fact that they were conducted in different patient populations, with different therapies at baseline. Furthermore, the National Institute for Clinical Excellence in the UK, considered that the drug was not cost effective. A post hoc analysis of the Phase III trials was performed to evaluate if belimumab would offer additional benefit to patients with renal involvement receiving mycophenolate mofetil (MMF) at baseline. Belimumab promoted renal improvement, although the differences between groups in most renal outcomes were not significant. Of note, this analysis included a small number of patients and those with severe active LN were excluded. Furthermore, a pooled multivariate analysis of the Phase III trials showed that the therapeutic effect of belimumab was especially obvious in the more serologically active patients with high anti-dsDNA antibodies and low C3 levels. Despite its mixed results, the drug has been approved by the Food and Drug Administration and the European Medicines Agency for use in SLE.

Belimumab is able to bind to soluble, but not membrane BAFF, thus the only mechanism of action is a reduction of signaling through the BAFF receptors by removing soluble BAFF in circulation. As belimumab does not bind to APRIL, signaling through BAFF receptors is only partially blocked. It is possible that APRIL may rescue some B cells from the anti-CD20 effects of rituximab and BAFF-neutralizing effects of belimumab.

**Atacicept**

Atacicept is a fully human recombinant fusion protein containing the BLyS/APRIL-binding extracellular portion of the TACI receptor fused to a slightly modified Fc portion of human IgG1. Unlike belimumab, this agent neutralizes both BLyS and APRIL, and prevents them from binding to their receptors on lymphocytes. Blockade of both cytokines indirectly affects mature B and plasma cells by inhibiting B cell survival after the T1 transitional stage, while sparing B-cell progenitors and memory B-cells. Levels of serum IgG, IgM, and IgA and numbers of mature and total circulating B cells are reduced by atacicept. Hence, in theory atacicept should be a viable and effective therapeutic option.

In order to evaluate its efficacy and safety, atacicept has been studied in animal models and in patients with RA, MS, hematological conditions, and SLE.

**Preclinical studies**

Immunological differences were observed between SLE-prone mice in which both BLyS and APRIL were eliminated or neutralized and mice in which only BLyS was eliminated or neutralized. Greater immunosuppression was observed in the former. B-1 cells are a subset of mature long-lived B cells. In a study by Gross et al B-1 cells were present in normal levels in mice in which only BLyS was neutralized, but were absent in TACI Ig Tg or treated mice. TACI Ig can neutralize heterotrimeric BLyS and APRIL. This suggests that both BLyS and APRIL are needed for the development and survival of the B-1 cell population. In animal models of RA, neutralization of both BLyS and APRIL was shown to reduce disease activity.

A reversible sub-total depletion of B cells and reduction in circulating Ig (especially IgM) levels were documented in preclinical studies with atacicept in mice and cynomolgus monkeys. The only evident systemic toxicity was transient elevation in liver transaminases (without any histological changes in the livers). Delays in the development of proteinuria and increased survival were observed in autoimmune-prone lupus mice treated with atacicept. Atacicept was also effective in the animal model of MS. In a rat model of optic neuritis, intraperitoneal treatment with 100 or 200 µg of atacicept resulted in increased apoptosis of retinal ganglion cells. The extent of inflammation, demyelination, and axonal loss of the optic nerve was more pronounced with this dose level compared to lower doses.

**Clinical studies in healthy volunteers, RA, MS, and hematological malignancies**

In a Phase I study healthy volunteers were given atacicept or placebo. The 70, 210, and 630 mg doses demonstrated a dose-dependent biological effect on IgM levels, with no treatment-related effects on IgG levels or lymphocyte subpopulations. Subsequent human trials with atacicept have demonstrated a reduction in total serum Ig levels.

Several studies were performed to determine the efficacy of atacicept in the treatment of RA. A Phase Ib dose-escalating study was undertaken in 73 rheumatoid factor (RF)-positive patients with active, moderate-to-severe RA. Atacicept or placebo were given as single (70, 210 or 630 mg) or repeated doses (three doses of 70 or 210 mg, or seven doses of 420 mg) every fortnight. Median IgG, IgA, and IgM values were reduced by 21%, IgA 37% and 54% respectively compared to baseline. This is about double the reduction seen in belimumab treated patients (in a Phase II study, reductions of 10%, 14%, and 29% were observed, respectively, in the serum concentration of IgG, IgA, and IgM, after belimumab, compared with a reduction inferior to 5% in the placebo...
Nevertheless, the dose-dependent reduction of Ig and RF levels was also observed. Like the Phase Ib study, there were no statistically significant reductions of anti-cyclic citrullinated peptide antibody levels. In AUGUST II, 311 TNF antagonist-naive patients with RA in whom TNF antagonist therapy had failed, were given three different doses of atacicept (25, 75 or 150 mg) or placebo, twice weekly for 4 weeks, then weekly for 21 weeks, with a 13 week treatment-free follow-up period (until week 38). In those receiving atacicept, IgM, IgA, and IgG levels decreased, in a dose-dependent manner, from the first dose to week 26. RF levels were also reduced at week 26. Both effects on total Ig and RF were reversible after atacicept was discontinued. There were no statistically significant reductions of anti-cyclic citrullinated peptide titers.

Two Phase II trials focused on efficacy, safety, and biological activity of atacicept in patients with active, moderate-to-severe RA. The primary endpoint was a 20% improvement in disease severity according to the ACR criteria, assessed using the C-reactive protein level (ACR20-CRP), at week 26. In AUGUST I, 256 patients with RA in whom TNF antagonist therapy had failed, were randomized to either single or repeated doses of atacicept or placebo, twice weekly for 4 weeks, then weekly for 21 weeks, with a 13 week treatment-free follow-up period (until week 38). In those receiving atacicept, IgM, IgA, and IgG levels decreased, in a dose-dependent manner, from the first dose to week 26. RF levels were also reduced at week 26. Both effects on total Ig and RF were reversible after atacicept was discontinued. There were no statistically significant reductions of anti-cyclic citrullinated peptide titers. In AUGUST II, 311 TNF antagonist-naive patients with RA in whom the response to methotrexate treatment was inadequate received either placebo, atacicept 150 mg weekly, or with or without a 4 week loading period (twice weekly dosing), or open-label adalimumab 40 mg every other week, for 25 weeks. As in the former study, Ig and RF levels decreased in patients randomized to atacicept, whereas in the group of patients given adalimumab, a slight, non-statistically significant increase in the three Ig classes and RF levels was observed. Like the Phase Ib study, there was a reduction of absolute levels of mature B cells and plasma cells from baseline to week 26 in the atacicept treated groups. During the course of atacicept treatment, the number of memory B-cells transiently increased.

AUGUST I and AUGUST II failed to reach the primary endpoint. In AUGUST I, atacicept had no significant effect on the ACR20-CRP, ACR50-CRP or ACR70-CRP response rates. In AUGUST II the ACR50-CRP showed significantly greater response rates in the atacicept groups, although lower than in the adalimumab group, as compared with placebo. Nevertheless, the dose-dependent reduction of Ig and RF levels as well as the decrease in circulating levels of mature B and plasma cells, demonstrated the biological activity of atacicept.

A recent randomized, placebo-controlled, double-blind, Phase 2 trial showed an increased rate of relapse with atacicept treatment in patients with relapsing-remitting MS. This increase in clinical disease activity occurred in parallel with reductions in serum Ig concentrations and mature B-cell counts as reported in previous atacicept studies.

Atacicept was also investigated in hematological conditions resulting from clonal proliferation of lymphocytes and plasma cells. A Phase Ib clinical trial to investigate the tolerability and biological activity of escalating doses of intravenously administered atacicept in patients with refractory or relapsed CLL was performed. The results showed that patients treated with high dose atacicept (27 mg/kg) experienced stable disease or partial response. In contrast, progressive disease was observed in patients treated with low dose levels (1 and 4 mg/kg). In studies performed in patients with relapsed or refractory B-cell non-Hodgkin lymphomas, multiple myeloma and Waldenstrom’s macroglobulinemia, atacicept was well tolerated and had biological activity with a decrease in all polyclonal Ig isotypes and a substantial decline in circulating Ig-producing cells. However, tumor responses were not observed.

Atacicept in SLE
Atacicept has been studied in patients with SLE. A Phase Ib double-blind study in 49 patients with SLE who were randomized to either single or repeated doses of atacicept or placebo included patients who had mild to moderate SLE, but had not used MMF, cyclophosphamide, azathioprine, or methotrexate within 8 weeks of enrollment. Dosing regimens ranged from 0.3 to 9 mg/kg, including single and multiple doses. After an initial increase, a dose response reduction in B lymphocytes was observed in all atacicept groups. No reduction in T cells, monocytes, or natural killer cells was observed. There was a reduction in Ig levels, which was more evident in IgM levels although IgG and IgA levels also declined. Both Ig and B-cell responses were greatest in the repeated dosing regimens and were maintained at day 64 suggesting a lasting effect of atacicept. Favorable safety and tolerability profiles were demonstrated. In another Phase Ib study patients with mild-to-moderate SLE were randomized to receive atacicept single dose: 3, 9 or 18 mg/kg; or multiple dose: 2x9 mg/kg; or placebo. Patients were assessed for 6 weeks, except those in the 2x9 mg/kg cohort who were followed for 9 weeks. The biological activity of atacicept...
was demonstrated by a reduction of B-cells and Ig levels. IgM levels showed the greatest declines with treatment, followed by IgA and IgG. Atacicept was well tolerated, both systemically and locally.

A randomized Phase II/III trial of atacicept was designed to assess whether atacicept could prevent flares in patients with active lupus treated with a course of corticosteroids (CS). Patients were randomized to atacicept 75 mg or atacicept 150 mg administered subcutaneously, or placebo twice weekly for 4 weeks, then weekly for 48 weeks. Two fatal infections occurred in the 150 mg atacicept arm, leading to premature termination of this group. Primary endpoint analysis was thus only performed in the 75 mg and the placebo arm. There was no significant difference in the adjudicated flare rates in the placebo and the 75 mg atacicept arm (flare rates of 58% and 54%, respectively; odds ratio [OR] 1.15 [0.73 to 1.80], \( P = 0.543 \)). Post hoc analysis of the primary endpoint suggested a beneficial effect in the atacicept 150 mg regimen with a significant reduction in the proportion of patients with flares compared with placebo (flare rate 37% and 54%, respectively; OR 0.48 [0.30 to 0.77], \( P = 0.002 \)). Flare rates were analyzed among patients who completed treatment prior to discontinuation of the 150 mg arm. Atacicept 75 mg had no significant benefit versus placebo (flare rate 58% and 60%, respectively; OR 0.89 [0.48 to 1.67], \( P = 0.724 \)), but there was a significant reduction in the flare rate in the 150 mg arm compared to placebo (43% and 60%, respectively; OR 0.49 [0.26 to 0.92], \( P = 0.027 \)). The high-dose treatment was also associated with a significantly delayed time to first flare compared with placebo (hazard ratio 0.56 [0.36 to 0.87], \( P = 0.009 \)). There was a dose dependent decrease in the proportion of subjects who had at least one increase in CS dose to \( \geq 20 \) mg/day, which suggests that atacicept may have steroid-sparing benefit. Both 75 and 150 mg doses induced a similar reduction in anti-dsDNA antibodies. Atacicept was associated with reductions in B-cells, plasma cells and total Ig levels, and increases in C3 and C4 levels. Although the beneficial effect on C3 and C4 was more evident in those treated with atacicept 150 mg, it remains unclear why the clinical response appeared at 150 but not 75 mg of atacicept.

The atacicept 75 mg arm failed to reach the primary endpoint of reducing the number of SLE patients who had a new flare. Results with the dose of 150 mg were encouraging and it is very probable that the higher dose of atacicept was effective. However, safety concerns about the risk of infection were raised. Nevertheless, as the frequency of flares may have a significant impact in the clinical outcome, it is worth investigating strategies that might reduce the flare rate.

It has been suggested that APRIL could be a potential biomarker for predicting hard-to-treat cases of LN, and the use of APRIL antagonists such as atacicept has been proposed for the treatment of LN patients with high APRIL serum levels. A Phase II/III randomized, double-blind, placebo-controlled clinical trial was initiated to evaluate the efficacy and safety of atacicept in patients with active LN who had recently started immunosuppressive therapy with CS and MMF. An unexpected decline in serum IgG and serious infections occurred, leading to early termination of the trial after only six patients had been enrolled. As a result, no efficacy evaluation took place. These results are likely to be explained by factors discussed later in this article.

**Atacicept: concerns about tolerability and safety**

Concern has been raised that patients treated with atacicept might have a greater potential for developing serious adverse events (AEs) related to immunosuppression and consequent serious infections.

In the Phase 1 studies conducted in healthy volunteers, in patients with moderate to severe RA and in patients with SLE, atacicept was found to be well tolerated. There was no significant increase in the frequency of infection-related events between patients who received atacicept and those who received placebo.

In AUGUST I although the overall AEs, AEs leading to discontinuation and serious AEs (SAEs) were more frequent in the atacicept groups, there were no dose-dependent trends in AEs. There was no difference in terms of infection-related AEs between placebo and atacicept groups. In two patients randomized to the 150 mg group, three serious infection-related AEs were reported. One patient from the atacicept 25 mg group died from postoperative sepsis and one patient who was receiving atacicept 75 mg died of sudden cardiac arrest, but the latter was considered unlikely to be related to treatment.

In AUGUST II patients treated with atacicept had a higher frequency of AEs than those receiving placebo. Patients treated with atacicept 150 mg had a slightly higher incidence of infection-related AEs compared to those receiving placebo (35% versus 29%). While no serious infections were reported in patients randomized to atacicept, one patient treated with placebo had cellulitis and three cases of SAEs were reported in the adalimumab group (two cases of pneumonia and one case of disseminated tuberculosis). Five patients, each previously randomized to atacicept, developed a tumor (four...
benign tumors and one breast cancer). One patient treated with atacicept died of sudden cardiac arrest. This patient had a history of diabetes and hypertension.

In both AUGUST I and AUGUST II, median IgG levels remained above the lower limit of normal throughout the study, and no patient discontinued atacicept because of IgG levels below 3 g/L. In two patients treated with atacicept, median IgG levels remained above the lower limit of normal throughout the study. Only two patients reached IgG levels below 3 g/L, and, even in those, no serious infections were reported. Of note, the infections in the two patients who died were not associated with hypergammaglobulinemia. The incidence of infection was not influenced by the degree of decline in IgG or IgM levels. Moreover, although the rate of total infections and serious infections was slightly higher with atacicept 150 mg, in neither atacicept arm was the risk of serious infection statistically significantly increased compared with the placebo arm. Also, the overall similarity in AEs between the three arms of the study, including SAEs, was reassuring. The rate of serious infections in the BLISS 76 study (7% and 7.3% in the 1 and 10 mg/kg arms, respectively) was virtually identical to the 6.9% observed in the atacicept 150 mg arm of the Phase II/III study. In the EXPLORER trial of rituximab in patients with non-renal SLE, the rate of serious infections was even higher (17% in the placebo group and 9.5% in the rituximab group), perhaps reflecting the more intensive use of steroids and immunosuppressives. These results suggest that the underlying disease, steroid therapy, and delays in diagnosis and treatment may have been contributing factors to the deaths observed in the Phase II/III atacicept study.

The Phase II/III trial of atacicept in patients with LN was terminated early due to safety concerns. By the first day, serum IgG levels had substantially declined in patients who were randomized to atacicept compared with placebo and IgG decline continued following initiation of atacicept. Among the atacicept-treated patients, three developed serum IgG below the discontinuation threshold of 3 g/L, two of whom developed serious pneumonia. The results can be, at least partially explained by factors other than atacicept itself. First, the drop in IgG began 2 weeks before the initiation of atacicept, when MMF and high-dose steroids were initiated. Of note, a decline in IgG synthesis was reported in a patient with SLE after high-dose steroids therapy. Furthermore, hypergammaglobulinemia has been reported in approximately half of renal transplant patients who received MMF and steroids and an increased risk of infection has been observed in other LN studies during the induction phase with MMF and high-dose CS. These results raise the possibility that severe hypogammaglobulinemia might be responsible for this increased risk of infection. Secondly, by chance, the patients who were subsequently randomized to atacicept had higher proteinuria, at screening and through to day 14, than those given placebo. They also had urine protein:creatinine ratios ≥ 3.0 mg/mg at screening. The extent of IgG decline (up to 57% in the 2 weeks before atacicept initiation) suggests that an abnormally elevated excretion of IgG in the context of heavy proteinuria and a decrease in IgG production secondary to MMF and steroids administration may have played a role. The pharmacokinetics of atacicept may also have been influenced by the high levels of proteinuria. However, the true impact of higher proteinuria and reduced glomerular filtration rate on atacicept secretion is unknown as baseline glomerular filtration rate was lower in the patients who received atacicept. The two patients who developed serious pneumonia had lymphopenia and low CD4+ counts. In fact, lymphocyte counts were low in all patients at baseline, before MMF administration, which could be explained by active lupus, as well as CS use. Overall it is evident that the risk of infection associated with the use of atacicept (in those patients) is not different from that of other biologic agents notably belimumab and rituximab.

Conclusion
Identifying new therapies with improved risk to benefit ratio is needed, particularly for patients with SLE who do not respond satisfactorily to conventional therapies (steroids and immunosuppressives). Several studies suggest that BLyS and APRIL play an important role in the pathogenesis of autoimmune diseases, including SLE. Moreover, it has been reported that neutralizing both BLyS and APRIL might be more effective than neutralizing BLyS alone. Hence, atacicept emerges as an attractive therapeutic option. Its biological activity has been demonstrated in numerous studies performed in animals as well as in patients with autoimmune diseases, including SLE. In the study designed to evaluate atacicept in the prevention of flares in patients with SLE, the results with the dose of 150 mg were also encouraging. With regard to safety concerns, careful interpretation of the data is reassuring. The results of the atacicept trial in patients with LN suggest that minimizing the use of concurrent immunosuppressive medications, notably mycophenolate, may diminish the risk
of infection while improving clinical response. Atacicept may provide an added value in treating autoimmune conditions such as SLE and further investigations are warranted to establish its efficacy and safety in these diseases.

Acknowledgment
We thank Dr Claudia Pena Rossi for her constructive criticism of the manuscript.

Disclosure
Professor David Isenberg has in the past acted as a consultant for Merck Serono. The honoraria provided were passed onto a local arthritis charity. The remaining authors have declared no conflicts of interest.

References


